3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Sarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
bexmarilimab
×
Clear all
NCT05104905
2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2
Withdrawn